Total - 株式会社 矢内原研究所
Contents
1. D D D Total GPIO D D GIP 3 42 000 GIP 14217 0000000000 000000 YK253 Human GIP Total ELISA v U U total GP 0 D 0 0 0 0 U U Y 3 10 200 pM D D D 0 0 0 0 DD D U 000000 Y 400 00 duplicate 0 O 000000 2000 v 0000 35000000000 30000000 v00000000000000000 4 v 0000 SOALU D U 50000000 00000000800000000000000 6000 0000000000000000 700000 880000000000 000000 20 SQV 000000000 00000 5000000000 U D D DD DDD DD DD D total GP DDD D D DD 000 LI U D UD D D total GP D D D D D D D D D 0 0 D 0 D D D D D D D D D 0 D U U U 0 0 0 0 0 0 0 D D 0 D D D D UD D D U D UD D D UD U U D D D 0 D D U 0 U OU GP D D D D D D D D D D U 91 D 0 D D D 00 D D D D D D D D U 00 LI LI LI LI CE LI EJ EJ EJ EJ U U 000 00000 human GIP 1 42 1GIP 3 42 O O 00000 Uglucagon GLP 1 7 37 GLP 1 7 36 NH GLP 1 9 36 NH gt human GLP2 1 I 0 IU D 0 D D 0 0 0 0 0 0 D 0 00 U D D D D D D UD D D D D D D 0 D D 0 D 0 0 0 D D UD D 0 DU 960000 00000 GP D D 0 D D D D D D D D D 0 D D D D D 0 D 0 D D 0 D U U UD D D 0 D 0 D 0 D D D D 0 D D D D 0 D D D D D U D U D D D D D D D D D D D D D D 0 D 0 D 0 0 D 0 0 D D D D D D 0 D U 00000 HRP D D D 0 D D D D total GP D D 0 D D 0 0 U oaan El Et C pec C C2. A LI Q Tu ii 00000 0000 0 U 00 U U U 1 96 GP 2 0 4 pnol GP 3 12 nh He S 4 12 nh Ga wa on 12 nh 1M 6 25 mb YA 50 ni 1 Tween 20 8 V 000 U D UD D D D D D D D D D D D D D 0 UU D D UD D D 0 0 D 0 D D D D 0 D D UL 0000000000000000 00 1 0000000000000025 UL 1 mLIT 80000 12 0 0 0 0 0 0 0 0 U 0000000000001 2 UU UU DU UU D D D D D D D D U U 450 nm U O00 300000000000 3 0 0 000 000000000000 4 UU DUDU U 0 DD 00 0 0 D 0 U 5 01000000000000000000000000000000000000 U U U 0 D 0 D U 0 0 D
3. LI LI LI LI YK253 Human GIP Total ELISA il 12 sb li del FOR RESEARCH LABORATORY USE ONLY 0000 U D DD 0 U 418 0011 2480 1 FAX 0544 22 2770 TEL 0544 22 2771 Website www yanaihara co jp E mail ask yanaihara co jp 1 D 0 D 0 D U V 000 V 00000 U VI OL UL ML DU 0 0 0 0 U 0 0 0 U VIII Hm 50 6 8 11 12 12 13 YK253 Human GIP Total ELISA 0000 D 0 H in irin B N A E LA U U DD D D D 00 D D D DD D D D D D D DD UD D UD D D UD D UD D D D GP glucose dependent insulinotropic polypeptide GLP 1 glucagon like peptide 1 20 00 0000 D D U GIP 197000 Brown D D 0 D 0 0 D D D 0 D 00 D 0 D 0 0 D 0 D U 42000000000000000000 2000 GP 000 orp 000000 0 0 000000001800 3400 2000000000000000 0 0 OTakeda 0 200 GcP000000000000000GPO VP00000 0000000000000 U DU D D UD D U U D D D 0 D U 0 0 U cP0000000000000000 KOUOLUOOUOUCDOOBOOUDO 0 0000 0000000000000 000000000000 6 0 000 0 0000 00 00000000000000 cP00C00000000000000000 DGP 0000800000000000000002000000000000000040 U D D D DUD D D 0 D D D D U UD GP D D D D 0 D D D 0 0 D 0 D D 0 D 0 D D D D UL 000000000 2 U D GIP 1 42 DPP 4 D D D D D D D D D D D 0 LGIP 3 42 00 000 00 0000000000000000000000000DPP 40000 Qp 0 0 D D 0 U D D D D U GIP D D D D 0 D D D D 0 D D D D D D D DUD D 0 D D D D D D D D D 0 U EU a Ea Eat
4. 7 Krarup T Madsbad S Moody A Regeur L Faber OK Holst JJ Sestoft L 1983 Diminished immunoreactive gastric inhibitory polypeptide response to a meal in nevvly diagnosed type 1 insulin dependent diabetics Clin Endocrinol Metab 56 1306 12 8 Naitoh R Miyavvaki K Harada N Mizunoya VV Toyoda K Fushiki T Yamada Y Seino Y Inagaki N 2008 Inhibition of GIP signaling modulates adiponectin levels under high fat diet in mice Biochem Biophys Res Commun 376 21 5 9 Miyavvaki K Yamada Y Yano H Niwa H Ban N Ihara Y Kubota A Fujimoto S Kajikawa M Kuroe A Tsuda K Hashimoto H Yamashita T Jomori T Tashiro F Miyazaki J Seino Y 1999 Glucose intolerance caused by a defect in the entero insular axis a study in gastric inhibitory polypeptide receptor knockout mice Proc Nari Acad Sci USA 96 14843 7 12 10 Miyawaki K Yamada Y Ban N Ihara Y Tsukiyama K Zhou H Fujimoto S Oku A Tsuda K Toyokuni S Hiai H Mizunoya W Fushiki T Holst JJ Makino M Tashita A Kobara Y Tsubamoto Y Jinnouchi T Jomori T Seino Y 2002 Inhibition of gastric inhibitory polypeptide signaling prevents obesity Nat Med 8 738 42 11 Tsukiyama K Yamada Y Yamada C Harada N Kawasaki Y Ogura M Bessho K Li M Amizuka N Sato M Udagawa N Takahashi N Tanaka K Oiso Y Seino Y 2006 Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion Mol Endocrinol 20 1644 51 00000
5. 0 D 0 0 D D 0 D 0 0 D U 6 U U UU D U D 0 1000 mL 7 00000000001 0000000 1 U U 0000000000000000 1 mL U 11111 LU DD 10 4 pmol mL 400pM D U D D 0 0 D D D D U D D D D 0 2 mL D 0 D DD 0 D 0 D 0 2 mL D U U D 200 pM D I D D D D D D D D D 0 D 0 D D D D D D D U U U 100 50 0 25 0 12 5 6 3 3 1 pM D D D O ODO U OU D D 0 pM D D D D DDD 0 0 D 0000 0 0 000000000000 2 1 pMI 200 pM 2 0000000000000 50mL D 0 D D 0 0 0 950mL I D D D 0 0 D D 0 3 UU UU DU DU DD D D DD D 0 0 0 D 0 0 0 U U D U 000000 1 000000000200 30 0 D 01 U U U 0 DU D D 0 0 DU D D 0 0 D U D D 0 0 D 0 0 0 U 2 DDD DDD DDD 350 UL OI DD D D DDD D 0 0 0 0 0 0 DD 0 0 D U D 0 U U U U 0 D 0 D D 0 0 D U D 0 0 D D UU D D 0 0 D D 0 D 0 0 D D 0 0 0 D D 0 0000000000000 200000000 30000000000 3 0000000 5020 0 0 00 0 0004 0 3 1 6 3 12 5 25 0 50 0 100 200 pM 00000 500200000 4 10000000000000000000000000 20 100 2 0000000000040000 U 100 20 0000 JO D 000000000000000 1090090000 100 0000 0000000000000000000 0 2 0041000000000 40000 100 HL D D D D D 0 D D 0 D 0 D D D D U 30000000 U 000 100nL D I U 0 U U U U D D D D 450nm 620mU D D D 0 D D D 0 U U 00000 SU or 411
6. Parameter U D U D D D U D GIP D D U U 0000000000000 srPH1111111101011 10 U IOUULUUUUU UD D D 0 D D D D 0 D D D D 0 D D D D 0 U U U D D D D D D 0 D D D 0 D D D D D GP D D D D D D 0 0 U V 000000 000 2 0 0 0 0 UD D 0 0 0 0 O OD U YK250 Human GIP Active ELISA D DU 0000000000 GIP 1421 D D D 0 0 00 00 000 YK253 0000 SIPa 42 0 GIP3 4 0 00000000 inhibitor 0 01ml mL Catalog No DPP4 MILLIPORE 1 D 000000000000 0 01 0000 BD P800 GLP 1 GIP Glucagon Ghrelin H H 0000000001 0000000000 00 0000 0 DOO DUO DOO DU DD DD O U O DI 1 300 D D O D OU D D D DD 0 0000 0 00 0 0 0 0 OD O O DI U U U U U U 00000 0000 LI LI LI U DUD D DU D DD 0 0 D D 0 D D UD U 0 D D D D 00000000000000000000100 30 C 00 20000000 00 U U 0 0 0 0 0 0 0 0 D UU 0 0 0 0 D D 0 0 D D ra m m O Km 0000000000000000000 0 01 U U 0 D 0 0 0 0 0 D 0 UU D D D D 0 D D D 0 CJ U D UD D D D D 0 D D D D 0 D D D D 0 D D U D U L L 2 I L U M CI CI CI C I C I C EZ CI CI CI LI L U L U p M U U 0 0 0 D 0 0 0 D D 0 0 D oO Oo 0000000000000000000 0000002000000000 01 U D D D D D 0 D D U 0 100 mm 000000000 1000000000000000000
7. 00 0000 000000 O 418 0011 0000 0 0 0 0 0 2480 1 FAX 0544 22 2770 TEL 0544 22 2771 www yanaihara co jp ask yanaihara co jp 20150 80 31000 13
8. 000 U U D U 0 DU 0 00 D D D 0 D D D D 0 0 D D 0 D 0 0 D U 0000000000000 0 0 0 D D D 0 D 0 0 D D D 0 U O O O FT O OI OI OIL AE ET 51 Ey ET U D D D D D D D D D 0 D U D D D D D D 0 D D 0 D D 0 0 0 D D U UL U D DD D D D D D D D D D 0 D D D D D D D D D D D D D D D UL U U U 0 DU D D 0 0 DU D D 0 0 D 0 0 0 U LI LI LI LI CI C C LI LI LI LI LI EJ EJ EDEJEE ED EE EJ EH H VI 0000 Typical standard curve 10 00 100 E 3 A 0 10 0 01 1 10 100 1000 Human GIP pM 00000000 00000 AH Added GIP Observed Expected Recovery pM pM pM 0 25 8 4 30 6 29 8 102 7 20 45 5 45 8 99 3 80 95 4 105 8 90 2 00000 BD Added GIP Observed Expected Recovery pM pM pM 0 45 3 4 49 8 49 3 101 0 20 61 1 65 3 93 6 80 120 3 1253 96 0 00000 CH Added GIP Observed Expected Recovery pM pM PM 96 0 264 4 29 4 30 4 96 7 20 44 3 46 4 95 5 80 98 8 106 4 92 9 00000 D Added GIP Observed Expected Recovery pM pM pM 76 0 22 7 4 27 1 26 7 101 5 20 39 8 42 7 93 2 80 92 0 102 7 89 6 U U U D U ET Added GIP Observed Expected Recovery pM pM pM 70 0 8 8 4 11 7 12 8 91 4 20 26 6 28 8 92 4 80 89 5 88 8 100 8 0000000 00000 AH Sample dilution Observed Expect
9. Sample dilution Observed Concentration Mean pM pM pM X1 187 4 187 4 X2 101 0 202 0 X4 50 2 200 8 X8 24 9 199 2 197 4 0000000 000000 000000 ll Human 100 Glucagon lt 0 1 GLP 1 7 37 lt 0 1 GLP 1 7 36 NH2 lt 0 1 GLP 1 9 36 NH lt 0 1 Human GLP 2 lt 0 1 0000000 0000000000 CV 4 7 6 8 0000000000 V 5 21 5 5 000000 3 1 200 11 VID D 0 0 D 0 0 0 0 UL 0000 0000 20 SO 0000000000 000000 0200008 5000000000000000 0000 0000 960000000000000000 vig O L 1 Brown J C Mutt V and Pedersen R A 1970 Further purification of a polypeptide demonstrating enterogastrone activity J Physiol 209 57 64 2 Moody A J Thim L amp Valverde I 1984 The isolation and sequencing of human gastric inhibitory peptide GIP FEBS Lett 172 142 148 3 H Carlquist M Kvvauk S Otte SC McIntosh CH Brown JC Mutt V 1981 Amino acid sequence and heterogeneity of gastric inhibitory polypeptide GIP FEBS Lett 123 205 210 4 Moody AJ Damm Jorgensen K and Thim L 1981 Diabetologia 21 306 abstr Takeda J Seino Y Tanaka K Fukumoto H Kayano T Takahashi H Mitani T Kurono M Suzuki T Tobe T et al 1987 Sequence of an intestinal cDNA encoding human gastric inhibitory polypeptide precursor Proc Natl Acad Sci U S A 84 20 7005 8 6 Pederson R A 1994 in Gut Peptides Biochemistry and Physiology eds Walsh J H amp Dockray GJ Raven New York pp 217 260
10. ed Jo of Expected pM pM 70 KI 76 3 76 3 X2 36 5 38 2 95 5 X4 19 0 19 1 99 3 X8 9 7 9 5 102 0 00000 BO Sample dilution Observed Expected Jo of Expected pM pM 70 KI 32 1 32 1 X2 16 1 16 0 100 2 X4 8 8 8 0 109 5 X8 4 2 4 0 104 6 U U U U U CU Sample dilution Observed Expected Jo of Expected pM pM 70 KI 45 7 45 7 X2 22 8 22 9 99 8 X4 13 0 11 4 114 0 X8 6 6 5 7 115 2 U U U U U DU Sample dilution Observed Expected Jo of Expected pM pM 70 KI 63 5 63 5 X2 34 5 31 7 108 7 X4 17 4 15 9 109 7 X8 8 9 7 9 111 5 00000 EL Sample dilution Observed Expected Jo of Expected pM pM 70 KI 33 4 33 4 X2 16 8 16 7 100 4 X4 8 4 8 3 100 4 X8 4 3 4 2 102 6 0000000000000000 GIP Total O00 U U U U U AO Sample dilution Observed Concentration Mean PM pM pM XI Over X2 Over X4 Over X8 127 6 1020 8 1020 8 00000 BL Sample dilution Observed Concentration Mean pM pM pM XI Over X2 150 8 301 6 X4 84 7 338 8 X8 43 1 344 8 328 4 U U U U U CH Sample dilution Observed Concentration Mean pM pM pM XI Over X2 Over X4 171 6 686 4 X8 81 8 654 4 670 4 10 U U U U U DU Sample dilution Observed Concentration Mean pM pM pM XI Over X2 Over X4 124 4 497 6 X8 62 3 498 4 498 0 00000 EL Sample dilution Observed Concentration Mean pM pM pM X1 Over X2 Over X4 Over X8 100 4 803 2 803 2 00000 FU
Download Pdf Manuals
Related Search